Robert P. Whitehead

Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors

Jon Chung, Ninad Dewal, Ethan Sokol et al. · JCO Precision Oncology · 2019 · 160 citations · Full text

A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study

John S. Macdonald, Sheryl McCoy, Robert P. Whitehead et al. · Investigational New Drugs · 2005 · 148 citations

Swog 9924, Pancreatic Cancer, Gastrointestinal Oncology +7

Phase II Trial of High-Dose Intermittent Interleukin-2 in Metastatic Renal Cell Carcinoma: A Southwest Oncology Group Study

Ronald M. Bukowski, Phyllis J. Goodman, E. David Crawford et al. · JNCI Journal of the National Cancer Institute · 1990 · 98 citations

Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)

Philip A. Philip, Bryan Goldman, Ramesh K. Ramanathan et al. · Cancer · 2014 · 92 citations · Full text

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

Robert P. Whitehead, Cathryn Rankin, Paulo M. Hoff et al. · Investigational New Drugs · 2008 · 82 citations · Full text

Phase Ii Trial, Gastrointestinal Oncology, Medicine +10